Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
1.230
0.00 (0.00%)
At close: Jan 31, 2025, 4:00 PM
1.211
-0.019 (-1.54%)
After-hours: Jan 31, 2025, 7:20 PM EST
Sangamo Therapeutics Revenue
Sangamo Therapeutics had revenue of $49.41M in the quarter ending September 30, 2024, with 425.77% growth. This brings the company's revenue in the last twelve months to $52.29M, down -74.04% year-over-year. In the year 2023, Sangamo Therapeutics had annual revenue of $176.23M with 58.34% growth.
Revenue (ttm)
$52.29M
Revenue Growth
-74.04%
P/S Ratio
4.55
Revenue / Employee
$129,114
Employees
405
Market Cap
256.64M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 176.23M | 64.93M | 58.34% |
Dec 31, 2022 | 111.30M | 598.00K | 0.54% |
Dec 31, 2021 | 110.70M | -7.49M | -6.34% |
Dec 31, 2020 | 118.19M | 15.76M | 15.39% |
Dec 31, 2019 | 102.43M | 17.98M | 21.29% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
SGMO News
- 17 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out - Accesswire
- 18 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 19 days ago - Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 20 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation - Accesswire
- 22 days ago - Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 23 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Investors to Connect - Accesswire
- 24 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation - Accesswire
- 25 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation - Accesswire